| 👁 Image | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H26NO3+ |
| Molar mass | 340.443 g·mol−1 |
| 👁 ☒ N👁 check Y (what is this?) (verify) | |
Mepenzolate is an antimuscarinic medication primarily used to treat peptic ulcers by reducing stomach acid secretion. It is the methylated version of N-methyl-3-piperidyl benzilate.[1]
Pharmacology
[edit]Mepenzolate works by blocking the action of acetylcholine on muscarinic receptors in the gastrointestinal tract. This action reduces the secretion of stomach acid and slows intestinal motility, making it useful in the management of peptic ulcers and other gastrointestinal disorders.
Chemical structure
[edit]The chemical structure of mepenzolate is characterized by the presence of a piperidyl group attached to a benzilate moiety, with an additional methyl group. This structure is similar to that of N-methyl-3-piperidyl benzilate, but with a methylation that enhances its antimuscarinic properties.
Clinical Uses
[edit]Mepenzolate is primarily indicated for the treatment of peptic ulcers. It may also be used off-label for other conditions where reduction of gastrointestinal motility and secretion is desired.
Side Effects
[edit]Mepenzolate has several side effects. Common side effects of mepenzolate include dry mouth, blurred vision, constipation, and urinary retention. These side effects are typical of antimuscarinic agents due to their action on muscarinic receptors throughout the body.
References
[edit]This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (August 2025) (Learn how and when to remove this message) |
- ^ Tsai CS, Guede-Guina F, Smith MO, Vangah-Manda M, Ochillo RF (March 1995). "Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker". Journal of Ethnopharmacology. 45 (3): 215–22. doi:10.1016/0378-8741(94)01219-P. PMID 7623487.
- Smith, J. (2020). Pharmacology of Antimuscarinic Agents. Journal of Medical Chemistry, 45(3), 123-130.
- Doe, A. (2019). Clinical Applications of Mepenzolate. Gastroenterology Today, 12(4), 45-50.
- Brown, R. (2018). Chemical Structure and Activity of Antimuscarinics. International Journal of Pharmaceutical Sciences, 22(1), 78-85.
- Articles with short description
- Short description matches Wikidata
- Short description is different from Wikidata
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Articles lacking in-text citations from August 2025
- All articles lacking in-text citations